What Beavan v. Allergan May Mean for Expert Testimony in Eminent Domain Matters

One of the key functions of trial judges is to prevent undue prejudice in court by excluding unreliable testimony. Sometimes, that means excluding the testimony of expert witnesses. Expert testimony that is not backed by reliable methods or sufficient facts can lead juries to erroneous conclusions.

With that in mind, we take a look at a recent New Jersey Supreme Court decision, which underscores this indispensable function. The case, Beavan v. Allergan U.S.A., Inc., may have a particularly substantial impact in eminent domain litigation. Here is an overview of the case and the implications it has for eminent domain practitioners.

Background

In Beavan v. Allergan U.S.A., Inc., the plaintiff claimed that a defective eye drug caused severe injuries and blindness. The plaintiff relied on two expert witnesses, Dr. Lalezary and Dr. Phillips, to establish causation, an essential element of her case. Dr. Lalezary provided a written expert report, while Dr. Phillips did not.

At trial, the defense moved to exclude the testimony of the plaintiff’s experts. The trial court denied the motion and held that the testimony was sufficiently based in fact and data under N.J.R.E. 702 and 703. Further, the court held that the testimony did not constitute “net opinions” or unsupported conclusions.

The Appellate Division reversed the trial court’s decision. It held that both experts provided net opinions and therefore excluded their testimony. With the crucial testimony excluded, the plaintiff could no longer prove causation. As a result, the Appellate Division found that the defendant was entitled to summary judgment.

Appeal to NJ Supreme Court

The matter was timely appealed to the NJ Supreme Court. The legal issues before the Court were threefold. First, whether the trial court applied the correct standard in reviewing the expert testimony. Second, whether the expert opinions were “net opinions” as determined by the Appellate Division. Finally, whether summary judgment was properly granted in favor of the defendant.

In its decision, the Court cited In Re Accutane Litigation, which prescribed a rigorous reliability analysis of expert testimony. That case highlighted the gatekeeping role of judges and explained that they must evaluate the methodology of experts and the data underlying their opinions.

Here are the four Accutane factors for determining the reliability of expert testimony:

1. Testability: Whether the expert’s theory can be tested or falsified.
2. Peer Review & Publication: Whether the expert’s methodology has been published and reviewed by other experts in the field.
3. Error Rate & Standards: Whether the method has a known error rate and standards controlling how it is applied.
4. General Acceptance: Whether the method is accepted in the scientific community.

Importantly, these factors are not a mandatory checklist. Courts consider them flexibly, and other case-specific considerations may be used. The bottom line is that Accutane requires a rigorous review of expert testimony before it can be admitted to a jury.

Applying the holding in Accutane, the NJ Supreme Court held that the trial court did not properly exercise its gatekeeping role in admitting the testimony of both experts. Further, since the trial court failed to conduct the required reliability analysis, the Court held that the Appellate Division’s ruling was premature. It remanded the case back to the trial court for an Accutane reliability hearing.

Application to Eminent Domain

Although the Court’s decision arose in the product liability context, Beavan may be particularly significant for eminent domain litigation. Property owners frequently rely on expert witnesses who routinely prepare appraisal reports and offer testimony on their opinions of fair market value. Accordingly, expert testimony often becomes a decisive factor in eminent domain trials.

Courts have refined the standards judges must use when evaluating the reliability of evidence in eminent domain trials. For example, Caoili v. State of New Jersey addressed a threshold requirement for introducing evidence of a potential zoning change. Before a jury can consider such evidence, the judge must first determine that there is a “reasonable probability” that the change will occur. Likewise, State v. Gorga recognizes that the reasonable probability of a zoning change must be determined before the issue can be presented to a jury. Borough of Saddle River v. 66 East Allendale, LLC held that when the standards of reliability are met, juries may consider how the probability of a zoning change affects a property’s fair market value.

The standard of review for expert testimony described in Beavan carries significant weight in eminent domain cases. Judges are expected to do more than simply allow an appraiser to testify based on experience alone; they must assess whether the expert’s valuation methodology is grounded in sufficient facts and accepted appraisal principles. The implications of Beavan are especially important when an expert’s valuation depends on a claimed likelihood of future zoning changes. In those cases, testimony about a potential rezoning cannot rest on speculation or broad assumptions about future land use. Instead, it must be supported by objective facts, market evidence, planning history, and other data showing a reasonable probability that the change will occur.

Conclusion

Beavan reinforces the principle that eminent domain practitioners already know well: expert testimony can determine the outcome of a case, but its admissibility depends on whether it is supported by a reliable foundation. For property owners, condemning authorities, and appraisers alike, the decision is a reminder that valuation opinions must be supported by sound methodology, sufficient facts, and careful analysis before they ever reach a jury. As courts continue to emphasize rigorous gatekeeping, the reliability of expert testimony will remain central to achieving just compensation and fair results in condemnation proceedings.